PBSV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PBSV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2024-04-24), Pharma-Bio Serv's Intrinsic Value: Projected FCF is $0.95. The stock price of Pharma-Bio Serv is $0.70. Therefore, Pharma-Bio Serv's Price-to-Intrinsic-Value-Projected-FCF of today is 0.7.
The historical rank and industry rank for Pharma-Bio Serv's Intrinsic Value: Projected FCF or its related term are showing as below:
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Pharma-Bio Serv was 1.72. The lowest was 0.37. And the median was 0.79.
The historical data trend for Pharma-Bio Serv's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma-Bio Serv Annual Data | |||||||||||||||||||||
Trend | Oct14 | Oct15 | Oct16 | Oct17 | Oct18 | Oct19 | Oct20 | Oct21 | Oct22 | Oct23 | |||||||||||
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial | 1.07 | 0.93 | 0.82 | 0.79 | 1.01 |
Pharma-Bio Serv Quarterly Data | ||||||||||||||||||||
Apr19 | Jul19 | Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | |
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial | 0.89 | 0.83 | 0.97 | 1.01 | 0.95 |
For the Health Information Services subindustry, Pharma-Bio Serv's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, Pharma-Bio Serv's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Pharma-Bio Serv's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)
In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)
Add all the Free Cash Flow together and divide 6 will get Pharma-Bio Serv's Free Cash Flow(6 year avg) = $1.10.
Pharma-Bio Serv's Intrinsic Value: Projected FCF for today is calculated as
Intrinsic Value: Projected FCF | = | (Growth Multiple | * | Free Cash Flow (6 year avg) | + | Total Stockholders Equity (Jan24) | * | 0.8) | / | Shares Outstanding (Diluted Average) |
= | (9.5203515959648 | * | 1.1024 | + | 14.156 | * | 0.8) | / | 22.986 | |
= | 0.95 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma-Bio Serv (OTCPK:PBSV) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Pharma-Bio Serv's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF | = | Share Price | / | Intrinsic Value: Projected FCF |
= | 0.70 | / | 0.94927501955067 | |
= | 0.74 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Pharma-Bio Serv's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Elizabeth Plaza | 10 percent owner | 363 DORADO BEACH EAST, DORADO PR 00646 |
Altura Victor Sanchez | officer: President and CEO | C/O PHARMA-BIO SERV, INC., 6 ROAD 696, DORADO PR 00646 |
San Juan Holdings | 10 percent owner | 255 PONCE DE LEON, SUITE 305 MCS PLAZA, SAN JUAN PR 00917 |
Pedro J Lasanta | officer: Chief Financial Officer | 373 MENDEZ VIGO, STE 110, DORADO PR 00646 |
Dov Perlysky | director | 2 LAKESIDE DRIVE WEST, LAWRENCE NY 11559 |
L P Venturetek | 10 percent owner | C/O DAVID SELENGUT ELLENOFF GROSSMAN, 370 LEXINGTON AVENUE 19TH FLOOR, NEW YORK NY 10017 |
Barron Partners Lp | 10 percent owner | 730 FIFTH AVENUE, 25TH FLOOR, NEW YORK NY 10019 |
Manuel O Morera | officer: Chief Financial Officer | 373 MENDEZ VIGO, SUITE 110, DORADO PR 00646 |
Mark A Fazio | officer: Exec. Vice President and COO | P O BOX 1026 GREEN STREET, PERKASIE PA 18944 |
Kirk Wheeler Michel | director | 209 EAST TRYON STREET, HILLSBOROUGH NC 27278 |
Irving L Wiesen | director | 1273 NORTH AVENUE, APT 1E 7, NEW ROCHELLE NY 10804 |
Howard Spindel | director | 39 BROADWAY SUITE 3300, NEW YORK NY 10028 |
Nelida Plaza Rodriguez | officer: Vice President and Secretary | G11 CALLE MADRE PERLA URB, DORADO DEL MAR, DORADO PR 00646 |
Krovim Llc | director, 10 percent owner, officer: Manager | P.O. BOX 339, LAWRENCE NY 11559 |
From GuruFocus
By [email protected] [email protected] • 03-17-2020
By ACCESSWIRE ACCESSWIRE • 09-15-2020
By ACCESSWIRE ACCESSWIRE • 06-15-2022
By ACCESSWIRE AccessWire • 04-12-2019
By [email protected] [email protected] • 09-16-2019
By ACCESSWIRE ACCESSWIRE • 09-15-2021
By ACCESSWIRE AccessWire • 04-12-2019
By ACCESSWIRE ACCESSWIRE • 02-01-2021
By ACCESSWIRE AccessWire • 04-12-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.